Bevacizumab biosimilar (Bio-Thera Solutions)

贝伐珠单抗生物类似药 (百奥泰生物)

Report date: 2025/06/16 16:57:57

Base Information

Drug NameBevacizumab biosimilar (Bio-Thera Solutions)
Drug Alias Name普贝希AVZIVIPOBEVCYBAT-1706GP-2019
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar
Mechanisms of ActionVascular endothelial growth factor A inhibitors
TargetsVascular endothelial growth factor A
Therapy Area/IndicationsSolid tumoursUterine Cervical NeoplasmsFallopian Tube Neoplasms +[13] 
Global Approved IndicationsUterine Cervical NeoplasmsFallopian Tube NeoplasmsCarcinoma, Non-Small-Cell Lung +[10] 
Approved Indications in ChinaCarcinoma, Non-Small-Cell LungColorectal Neoplasms
Original Approved Country/TerritoryMainland China
Original Approved Date2021/11/17
Country/TerritoryUnited StatesUkraineTaiwan +[17] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesBio-Thera Solutions Ltd
China Registration ClassN/A

Develop Information

Active CompaniesSandozBiomm SAFgk Representative Service Gmbh +[6] 
Inactive CompaniesN/A
Active IndicationsSolid tumoursUterine Cervical NeoplasmsFallopian Tube Neoplasms +[13] 
Inactive IndicationsN/A

Other Information

ATC CodeL01XC07
Related LinksN/A